Water deprivation changes naloxone binding in the rat brain

The significant relationship of drinking to brain opioid receptors was determined using naloxone, a preferential antagonist of opioid mu receptor, in water-deprived rats. Whereas 48-hour food deprivation did not affect naloxone binding in any brain regions, 48-hour water deprivation caused a significant decrease in naloxone binding in the striatum, but not in the other brain regions. The striatal naloxone binding was found to progressively decrease with a period (0-48 h) of water deprivation. No significant change in naloxone binding in the hypothalamus or midbrain was observed during water deprivation. Water deprivation did not change the affinity constant of naloxone binding in the striatum. These observations indicate that the change in the striatal opioid receptors was specifically associated with thirsty sensation in the rat.     

纳洛酮对缺血再灌注海马细胞线粒体功能保护作用的研究

目的观察缺血再灌注期间海马细胞内游离钙离子、线粒体膜电位的变化以及纳洛酮对细胞的保护作用。方法20只新西兰大白兔随机分成4组对照组、缺血组、再灌注组、纳洛酮组,每组5只,然后以荧光染色流式细胞仪检测各实验组海马细胞内游离钙离子浓度和线粒体膜电位的变化。结果缺血组、再灌注组海马细胞内游离钙离子浓度显著高于对照组和纳洛酮组;其线粒体膜电位则低于对照组和纳洛酮组;再灌注组游离钙离子浓度明显高于缺血组;其线粒体膜电位则低于缺血组;对照组与纳洛酮组间各指标无显著差异。结论纳洛酮对缺血再灌注引起的海马细胞内钙离子浓度升高有抑制作用,对线粒体膜电位下降有一定的保护作用。     

Alleviation of brain edema by L-arginine following experimental subarachnoid hemorrhage in a rat model

Decreased levels of nitric oxide play a role in the development of cerebral ischemia secondary to subarachnoid hemorrhage (SAH). The protective effect of L-arginine on brain edema following SAH was investigated in this study. Rats were divided randomly into a sham-operated, a SAH+saline group and a SAH+L-arginine group. At different time points, brain water content was determined using the wet and dry weight compared method. Brain sodium content, potassium content and calcium content were detected using an atomic absorption spectral photometer. Somatosensory evoked potentials (SEP) were also detected. It was found that rat SAH models were successfully replicated. In the SAH+saline group, brain water and sodium content were significantly higher at 6 h and 24 h than those in the sham-operated group, while brain potassium content was statistically lower than that in the sham-operated group. Brain calcium content increased from 1 h to 24 h after induction of SAH. SEP latency progressively delayed. In the SAH+L-arginine group, increases in brain water content, sodium content and calcium content, as well as decreases in brain potassium content, were not as obvious as in the SAH+saline group. L-arginine partly prevented a delay in SEP latency. In conclusion, L-arginine, a substrate of nitric oxide synthesis, may relieve brain edema in rats with experimental SAH.     

Inhibition by naloxone of neutrophil superoxide release: a potentially useful antiinflammatory effect

The working hypothesis of many studies of shock has been that naloxone acts by blocking centrally and/or peripherally located opioid receptors. At plasma concentrations used to treat experimental shock (10(-6) M and above), naloxone inhibited the in vitro release of superoxide (O2-) by human neutrophils that were stimulated by the E. coli peptide N-formyl methionyl leucyl phenylalanine (FMLP). Superoxide release stimulated by phorbol 12,13-dibutyrate (PDB) was also inhibited by naloxone. Naloxone had no effect on the FMLP-stimulated release of beta-glucuronidase or lysozyme. Naloxone had no effect on 3H FMLP receptor binding. Studies utilizing 3H naloxone revealed the presence of a ligand-specific naloxone binding site on human neutrophils with a Kd of 1.2 X 10(-5) M, which is close to the ID50 of the inhibitory effect upon O2- release (1.8 X 10(-5). Thyrotropin releasing factor (TRF) had no effect upon 3H naloxone binding or on O2- release. Verapamil, a calcium channel blocker, inhibited 3H naloxone binding, and O2- release while nifedipine, another calcium channel blocker had no effect on either assay except at 10(-4) M, at which concentration 3H naloxone binding as well as the release of O2- were increased. These experiments suggest that the inhibitory effect of naloxone upon O2- release is mediated via a specific binding site.     

Naloxone increases the release of oxytocin, but not vasopressin, within limbic brain areas of conscious parturient rats: a push-pull perfusion study.

The influence of naloxone on the release in limbic brain areas of both oxytocin (OXT) and vasopressin, measured by radioimmunoassay, was studied in conscious parturient rats. Three consecutive 30-min push-pull perfusions (20 microliters artificial CSF/min) were made, via previously implanted guide cannulae, within the medio-lateral septum and dorsal hippocampus of parturient animals given saline or naloxone hydrochloride (5 mg/kg body weight) after delivery of the second pup. OXT release in the hippocampus, but not in the septum, was increased during parturition, compared to day 1 post partum. During the first 30-min collection period following naloxone administration, release of OXT was significantly elevated within the septum (44% compared to saline controls, p less than 0.002), but not in the dorsal hippocampus; vasopressin release was not affected. In contrast, on day 1 post partum, naloxone, administered 5 min after starting two consecutive perfusions failed to alter OXT release in septum or hippocampus in conscious rats. Naloxone, known to increase the release of OXT also from the posterior pituitary during parturition, speeded the parturition process significantly between the birth of pups 4 and 8 during push-pull perfusion of septum or hippocampus. The data suggest that endogenous opioid inhibition is involved in the regulation of central OXT release, but not vasopressin release, during parturition. Together with previous studies on OXT release from the posterior pituitary, it seems that during parturition there is coordinated endogenous opioid action on the release of OXT both into blood and into the brain.     

One month of streptozotocin-diabetes induces different neuroendocrine and morphological alterations in the hypothalamo-pituitary axis of male and female rats

LHRH (median eminence) and LH (pituitary and plasma) from male and female Sprague-Dawley rats were assayed 1 month after streptozotocin injection and compared with values in controls either fed ad libitum or offered a restricted diet. Plasma LH was also assayed after stimulation with exogenous LHRH or naloxone. In diabetic males, the median eminence LHRH content and the plasma LH response to exogenous LHRH were unaltered, pituitary LH was increased, and plasma LH was decreased under basal conditions and after naloxone treatment. In diabetic females, while the median eminence LHRH content and the plasma LH response to exogenous LHRH or naloxone were reduced, pituitary and plasma LH levels were not different. Measurements made in undernourished rats excluded the possibility that the alterations found in diabetic animals were nutrition dependent. In parallel experiments, hypothalami and pituitaries were examined morphologically. In diabetic animals, degenerate axons, mainly of the LHRH type, were found in the arcuate nucleus and median eminence, and LH gonadotrophs were altered and more numerous. Strong differences between control males and females were revealed by morphometry; moreover, diabetic females had higher brain weights and fewer LH gonadotroph changes than diabetic males. These studies indicate that 1) the hypothalamo-pituitary changes that occur early in our streptozotocin-treated rats are unrelated to undernourishment and are possibly caused by insulin deficiency; 2) the LHRH axonal lesions might play a primary pathogenic role in the hypothalamo-pituitary disorder; 3) some anatomical data indicate that the brain and pituitary are less severely affected by diabetes in female than in male animals; and 4) differences between control males and females may account for some of the dissimilarities between the sexes observed under diabetic conditions.     

Activation of gamma-aminobutyric acid B-receptors abolishes naloxone-stimulated luteinizing hormone release

Recent evidence suggests that the neurotransmitter gamma-aminobutyric acid (GABA) plays an important role in the control of gonadotropin secretion. The present study was conducted to identify the effect and site of action of different GABAergic drugs on LH secretion in vivo and to characterize the precise roles of different GABA receptors in these actions. Three different GABAergic drugs were used: muscimol and baclofen, which act at the level of the GABA A- and GABA B-receptors, respectively, and aminooxyacetic acid (AOAA), which increases the GABA content in the brain. The effects of these drugs were investigated in situations of enhanced LH secretion due to administration of naloxone or LHRH. In an initial experiment, adult male rats were treated ip with AOAA, followed by naloxone. AOAA treatment decreased basal LH levels and prevented naloxone-stimulated LH release. PRL levels were decreased by either AOAA or naloxone; however, the combination of these two drugs did not induce an additional or synergistic effect on the decreased PRL levels. In subsequent experiments, freely moving rats bearing Silastic cannulae in the right jugular vein received AOAA, muscimol, or baclofen a few minutes before either naloxone or LHRH administration. Baclofen and AOAA completely suppressed the naloxone-stimulated LH increase. Muscimol did not prevent the effect of naloxone. None of the three GABAergic drugs affected LH release in rats receiving LHRH. The results of these in vivo experiments suggest that the GABAergic system exerts primarily an inhibitory effect on gonadotropin secretion which is mediated at a central level, since pituitary responsiveness to LHRH is not affected by GABAergic drug treatment. GABA B-receptors are responsible for the inhibitory action of GABA.     

kappa-Opioid receptors also increase potassium conductance.

Decrease of calcium conductance induced by opioid agonists has been reported by others for mu-, delta-, and kappa-opioid receptors. On the other hand, only mu- and delta-opioid receptors have been reported to increase potassium conductance. Intracellular recordings were made from guinea pig substantia gelatinosa neurons in a brain slice. A subset of cells (29 of 83) were hyperpolarized by the kappa-opioid receptor agonist U69593 with an EC50 of 23 nM. The kappa-opioid receptor antagonist norbinaltorphimine (10 nM) blocked the hyperpolarization by U69593 but had no effect on the mu-opioid hyperpolarization present in these cells. Naloxone (300 nM) shifted the U69593 dose-response curve to the right, giving an estimated Kd for naloxone of 7.5 and 8.1 nM measured in two cells. The hyperpolarization caused by U69593 was mediated by a potassium conductance as determined with voltage clamp experiments. This demonstrates, depending on the cell type, that all three major opioid receptors (mu, delta, and kappa) can increase potassium conductance as well as decrease calcium conductance.     

Comparative evaluation of the effects of felodipine, hydralazine, and naloxone on the survival rate in rats subjected to a "fixed volume" model of hemorrhagic shock

Felodipine, a dihydropyridine calcium antagonist with potent arteriolar dilator properties, has been shown to enhance renal, mesenteric, coronary, and cerebral blood flows in intact animals as well as in man and to prevent deterioration of renal and mesenteric blood flows in Wiggers' model of hemorrhagic shock in dogs. In the present studies, efficacy of felodipine on 72 hr survival of rats subjected to an acute withdrawal of 40% of the blood volume was investigated. Shed blood was not reinfused in the present studies. Felodipine, whether administered before or after hemorrhage, facilitated dose-dependent increases in the survival rate up to 95%, whereas in the vehicle-treated group, the survival rate was 33%. Hydralazine, also an arteriolar dilator, in equi-hypotensive doses was not as effective as the calcium antagonist. Effects of felodipine are comparable to that of naloxone in enhancing survival. These data suggest that the salutary effects of felodipine can be related to its calcium antagonistic as well as arteriolar dilator properties.     

Opiate regulation of estradiol-2-hydroxylase in brains of male rats: mechanism for control of pituitary hormone secretion.

Treatment of male rats with a single high dose of morphine (10 mg/kg, subcutaneously) results in a dramatic suppression of brain estradiol-2-hydroxylase activity. The suppression is blocked by naloxone and is decreased upon the development of tolerance. The injection of naloxone (0.4 mg/kg) alone produces a significant increase in brain estradiol-2-hydroxylase activity over control levels. The effects of the opiate agonists and antagonists on the activity of this brain enzyme coincide in degree and direction with their effects on plasma lutropin (luteinizing hormone) concentrations. Because the 2-hydroxyestrogens were shown to induce pituitary lutropin release, the present results indicate that the action of opiates, endogenous or exogenous, on pituitary gonadotropin release can be mediated by brain catechol estrogens.     

Ovine brain areas sensitive to naloxone-induced stimulation of luteinizing hormone release

Previous work established that intravenous administration of the opioid receptor antagonist naloxone abruptly increased release of luteinizing hormone (LH) and decreased release of prolactin (PRL) in suckled anestrous ewes and also increased LH release in cyclic luteal ewes. The goal of the present research was to identify brain sites at which local unilateral infusions of naloxone would consistently duplicate the previously noted effects of intravenous naloxone. Intracerebral guide tubes were surgically implanted into the brain of 13 nonpregnant and 16 pregnant ewes at least 4 weeks prior to experimentation. Intracerebral infusion (20-40 microliters each through an inner cannula) was performed once daily during postpartum anestrus in suckled fall-lambing ewes and during recurring luteal states of the estrous cycle. Naloxone infusion (n = 142) usually consisted of 50 or 100 micrograms naloxone, although 5 ewes received 200 and 400 micrograms per infusion. Control infusions (n = 103) consisted of the vehicle for naloxone (i.e., 0.9% NaCl). Serum concentrations of LH and PRL were quantified at 10-min intervals from 90 min before to 100 min after infusion. Hormone data from individual ewes were grouped for least-squares analysis of variance based upon postmortem neuroanatomical identification of each infusion site. Unilateral intracerebral administration of naloxone consistently induced an increase in LH release within 20 min in the following two neuroanatomical groups:basal forebrain (n = 9 ewes) and chiasmatic area (n = 4 ewes).(ABSTRACT TRUNCATED AT 250 WORDS)     

Effect of an opiate antagonist (naloxone) on the gastric acid secretory response to sham feeding,pentagastrin, and histamine in man

We studied the effect of the opiate antagonist naloxone on the human gastric acid secretory response to three secretory stimulants: sham feeding, pentagastrin, and histamine. Intravenous naloxone (40 g/kg/hr) significantly inhibited the acid secretory response to sham feeding without affecting the serum gastrin response to sham feeding. Naloxone also significantly reduced pentagastrin- and histamine-stimulated acid secretion. These studies indicate that naloxone reduces acid secretion in response to all stimulants of acid secretion yet tested in humans.This study was supported by grants AM-16816 and AM-17328, from the National Institute of Arthritis, Metabolism and Digestive Diseases.Presented in part at the Plenary Session of the American Gastroenterological Association, Salt Lake City, Utah, May 19, 1980.     

Endorphins may function in heat adaptation.

Administration of the opiate antagonist naloxone to rats after acute or chronic heat exposure precipitates an increase in colonic temperature, an increase in escape attempts, and a decrease in body weight. These changes are accompanied by signs associated with hyperthermia such as salivation, diarrhea, and an abnormal extended posture. Although brain endorphin involvement is possible, hypophysectomy diminishes the intensity and magnitude of these naloxone effects, indicating that the naloxone effect in intact animals may be due to a functional antagonism of pituitary endorphins. These observations suggest that endorphins attenuate physiological responses to thermal and noxious stimuli triggered in common neuroanatomical pathways by heat.     

Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation

It has been hypothesized that brain opioid activity may be decreased in patients with the polycystic ovary syndrome (PCO) and that this decrease may, in part, explain the elevated levels of LH characteristic of the syndrome. We, therefore, examined the LH and PRL responses to naloxone infusions (2 mg/h for 4 h) in seven women with PCO and five weight- and estrogen-matched normal women. The infusions were given both before and after pretreatment with L-dopa-carbidopa (L-DOPA-C) because dopaminergic activity may be decreased in PCO, and dopamine may interact with the brain opioid system. Both PCO patients and normal women had similar responses of serum LH during naloxone treatment; the mean maximum LH responses were 53 +/- 15% (+/- SE) in normal women and 51 +/- 12% in PCO patients (P greater than 0.05). PRL levels were also unaffected by naloxone infusion. After L-DOPA-C pretreatment, baseline LH and PRL levels were unchanged in normal women and PCO patients, and the naloxone-induced LH rise was completely abolished in the normal women. However, in PCO patients, LH increased from 24.7 +/- 4 to 31 +/- 5 mIU/ml, with a mean maximum increase of 112 +/- 33% during naloxone infusion (P less than 0.05). We conclude that 1) brain or central opioid activity is not decreased in PCO; 2) increased central opioid activity does not appear to be responsible for the increased LH levels characteristic of the syndrome; and 3) decreased central dopamine activity and/or the interaction between the dopaminergic and opioid systems may be altered in PCO.     

Activity-dependent accumulation of calcium in Purkinje cell dendritic spines.

The calcium content of synapses of parallel fibers on Purkinje cell dendritic spines was determined by electron probe x-ray microanalysis of freeze-dried cryosections from directly frozen slices of mouse cerebellar cortex. In fresh slices frozen within 20-30 sec of excision, calcium concentrations ranging from 0.8 to 18.6 mmol/kg of dry weight were measured in cisterns of smooth endoplasmic reticulum within Purkinje cell dendritic spines. The average calcium content of spine cisterns in rapidly excised slices (6.7 +/- 0.6 mmol/kg of dry weight +/- SEM) was higher than the average calcium content of spine cisterns in brain slices incubated without stimulation for 1-2 hr before direct freezing (2.5 +/- 0.4 mmol/kg of dry weight). Depolarization of incubated cerebellar slices by isotonic 55 mM KCl resulted in the accumulation within spine cisterns of very high amounts of calcium or isotonically substituted strontium, both derived from the extracellular fluid. These results suggest that one function of spine cisterns is to sequester free calcium that enters the spine through ligand-gated or voltage-gated channels during synaptic transmission.     

Opiate antagonist in traumatic shock

In experimental animal studies, opiate receptor antagonists (such as naloxone) and physiological opiate antagonists (thyrotropin-releasing hormone [TRH] have been used with some success to improve outcome and physiological variables following traumatic shock associated with hypovolemia, spinal cord trauma, and head injury. Naloxone at high doses (in the mg/kg range) improves blood pressure and survival following hypovolemic shock in some species subjected to fixed-pressure shock. Similarly, naloxone treatment in the same dose range improves blood pressure and outcome following traumatic spinal shock as well as shock associated with traumatic head injury in selected animal models. The high doses of naloxone required in these studies suggest that the beneficial effects may be due to actions at relatively naloxone-insensitive opiate receptors, such as the kappa-receptor. Changes in the putative kappa-receptor ligand dynorphin are found after hypovolemic shock and traumatic injury to the brain or spinal cord. Opiate receptor antagonists with increased selectivity for the kappa-receptor may be superior to naloxone in the treatment of these conditions. TRH or TRH analogs similarly improve blood pressure and outcome following hypovolemic or spinal shock. Clinical trials of naloxone (at high doses) in human spinal cord injury have begun, and there are plans for clinical trials of naloxone in human head trauma and of TRH in human spinal cord injury.     

Alcohol and the Opiate Receptor

A number of in vivo studies have suggested that alcohol and the opiates may be integrally related in the brain. In this study we report that 0.1, 0.2, and 0.4% ethanol significantly increases the density of binding sites for [³H]naloxone in isolated brain membranes.     

Nufenoxole, a new antidiarrhoeal agent, inhibits fluid secretion in the human jejunum.

Nufenoxole is an orally active antidiarrhoeal agent which binds to opioid receptors in the brain and myenteric plexus of the intestine. A perfusion technique has been used to investigate the effect of nufenoxole (1 mg/kg intrajejunally) on water and solute transport stimulated by the secretagogue, dioctyl sodium sulphosuccinate, in the human jejunum in vivo. Nufenoxole reversed the direction of jejunal transport of salt and water from net secretion to net absorption. These changes in water and electrolyte transport were inhibited by intravenous naloxone, the opioid antagonist. Nufenoxole possesses potent antisecretory properties, which are mediated via opioid receptors and may contribute to its antidiarrhoeal action in man.     

Suppression of pulsatile LH secretion, pituitary GnRH receptor content and pituitary responsiveness to GnRH by hyperprolactinemia in the male rat

To assess whether gonadotropin-releasing hormone (GnRH) release from the hypothalamus might be altered by hyperprolactinemia in the male rat, we measured in chronically hyperprolactinemic rats the pituitary GnRH receptor content and described the pattern of luteinizing hormone (LH) release during the postcastration rise in gonadotropin secretion 24 and 72 h after gonadectomy. In intact rats, the effect of hyperprolactinemia was determined by describing the pattern of LH secretion, pituitary GnRH receptor content and assessment of pituitary responsiveness to small doses of GnRH (1.0 ng). In addition, to determine the role endogenous opioids might play in inhibiting GnRH release in hyperprolactinemic rats, we examined the effect of both a continuous infusion and a bolus injection of the opioid antagonist naloxone on the pattern of LH release. Chronic hyperprolactinemia was achieved by implanting 4 pituitaries under the kidney capsules 3-4 weeks before study. Acute hyperprolactinemia was achieved by injecting rats with 1 mg ovine prolactin every 12 h for 3 days. Control animals were untreated or were chronically hyperprolactinemic rats in which the hyperprolactinemia was transiently reversed by treatment for 3 days with the dopamine agonist 2-alpha-bromoergocryptine. The mean LH concentration was greatly decreased at 24 postcastration in chronically hyperprolactinemic rats relative to controls. This decrease was associated with a decrease in LH pulse height and pulse amplitude and pituitary GnRH receptor content, but not with an increase in the LH interpulse interval. In contrast, the decrease in mean LH concentrations in hyperprolactinemic animals at 72 h postcastration was primarily associated with a significantly longer LH interpulse interval than that observed in control animals. Chronic hyperprolactinemia in intact rats decreased the pituitary GnRH receptor content, in addition to decreasing the mean LH concentrations during pulsatile GnRH administration. Chronic hyperprolactinemia also inhibited LH release relative to controls during the continuous 4-hour infusion of naloxone and in response to a bolus injection of naloxone. However, in acutely hyperprolactinemic intact male rats a bolus injection of naloxone increase LH secretion 20 min later to levels similar to those obtained in control rats. In summary, these results indicate that chronic hyperprolactinemia decreased LH secretion by primarily decreasing GnRH secretion as suggested by a decrease in pituitary GnRH receptor content and a decrease in LH pulse frequency and pulse amplitude.(ABSTRACT TRUNCATED AT 400 WORDS)     

Alternative pathways for phospholipid synthesis in different brain areas during aging

Morphological and biochemical changes take place in the membrane of aged brain. In particular, studies on aged rats report alterations in brain phospholipid synthesis and in phospholipid-specific fatty acid composition. However, no significant changes in main phospholipid class content have been reported in aged brain, possibly owing to alterations in the alternative pathways for phospholipid synthesis during aging. Therefore, the present study was designed to determine the effect of aging on the enzyme activities responsible for phospholipid synthesis by alternative pathways. Indifferent brain areas of adult (3.5-month-old) and aged (28.5-month-old) rats we examined: 1) the activity of base exchange enzymes, which is a calcium-dependent, energy-independent and calcium stimulated enzymatic pathway; 2) phosphatidylethanolamine (PE) synthesis by phosphatidylserine decarboxylase activity (PSD); 3) phosphatidylcholine (PC) synthesis by transfer of methyl groups to endogenous PE by phosphatidylethanolamine N-methyltransferase activity (PEMT); 4) the synthesis of phosphatidylglycerol (PG) through phospholipase D (PLD) activity. Because the dependence on and the stimulation by calcium of base-exchange reactions is a well known mechanism and alterations in calcium levels in rat brain have been reported, we decided to investigate PS synthesis in the presence of endogenous and exogenous calcium (2.5mM). PS synthesis increased in cerebral cortex (CC) and cerebellum (CRBL) of aged rats with respect to adult rats in basal conditions (without the addition of exogenous calcium), but more significant changes were observed in serine base exchange activity during aging when exogenous calcium was added. PEMT activity in aged CC increased by 100%, the principal modification being observed in the first methylated product of the sequential reaction. Furthermore, the transphosphatidyl reaction was higher in aged brain as indicated by the increased PG synthesis. Our findings allow us to conclude that age affects some alternative pathways for phospholipid synthesis in the central nervous system, and indicate the presence of a compensatory mechanism to provide a pool of phospholipid classes for the maintenance of cellular membrane lipid composition during aging.